WO1996015234A3 - Lipidspaltendes enzym - Google Patents

Lipidspaltendes enzym Download PDF

Info

Publication number
WO1996015234A3
WO1996015234A3 PCT/EP1995/004414 EP9504414W WO9615234A3 WO 1996015234 A3 WO1996015234 A3 WO 1996015234A3 EP 9504414 W EP9504414 W EP 9504414W WO 9615234 A3 WO9615234 A3 WO 9615234A3
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
substrates
disclosed
lipid
target cells
Prior art date
Application number
PCT/EP1995/004414
Other languages
English (en)
French (fr)
Other versions
WO1996015234A2 (de
Inventor
Dieter Herrmann
Hans-Georg Opitz
Harald Zilch
Original Assignee
Boehringer Mannheim Gmbh
Dieter Herrmann
Opitz Hans Georg
Harald Zilch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19518278A external-priority patent/DE19518278A1/de
Application filed by Boehringer Mannheim Gmbh, Dieter Herrmann, Opitz Hans Georg, Harald Zilch filed Critical Boehringer Mannheim Gmbh
Priority to EP95937058A priority Critical patent/EP0791056B1/de
Priority to AU39278/95A priority patent/AU711367B2/en
Priority to NZ295682A priority patent/NZ295682A/en
Priority to JP51571796A priority patent/JP3681005B2/ja
Priority to DK95937058T priority patent/DK0791056T3/da
Priority to DE59510996T priority patent/DE59510996D1/de
Priority to AT95937058T priority patent/ATE292173T1/de
Publication of WO1996015234A2 publication Critical patent/WO1996015234A2/de
Publication of WO1996015234A3 publication Critical patent/WO1996015234A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Gegenstand der vorliegenden Erfindung ist ein bisher nicht beschriebenes membranständiges Enzym, das aus Zellmembranfraktionen von Blutleukozyten oder Monozyten/Makrophagen isoliert werden kann. Außerdem betrifft die Erfindung die Verwendung von Substraten dieses Enzyms zur Herstellung von Arzneimitteln, wobei die Arzneimittel diese Substrate als pharmazeutischen Wirkstoff enthalten. Die Arzneimittel eignen sich zur gezielten Freisetzung und Anreicherung von pharmakologisch aktiven Substanzen in entsprechenden Zielzellen. Gegenstand der Erfindung sind ferner In-vitro-Untersuchungssysteme, die dieses Enzym enthalten, zur Auffindung von weiteren Substraten dieses Enzyms.
PCT/EP1995/004414 1994-11-12 1995-11-09 Lipidspaltendes enzym WO1996015234A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP95937058A EP0791056B1 (de) 1994-11-12 1995-11-09 Lipidspaltender enzymkomplex
AU39278/95A AU711367B2 (en) 1994-11-12 1995-11-09 Lipid-splitting enzyme
NZ295682A NZ295682A (en) 1994-11-12 1995-11-09 Lipid cleavage enzyme complex and use in diagnostic testing to identify compounds that act as a ligand or substrate of the complex
JP51571796A JP3681005B2 (ja) 1994-11-12 1995-11-09 脂質切断酵素
DK95937058T DK0791056T3 (da) 1994-11-12 1995-11-09 Lipidopspaltende enzymkompleks
DE59510996T DE59510996D1 (de) 1994-11-12 1995-11-09 Lipidspaltender enzymkomplex
AT95937058T ATE292173T1 (de) 1994-11-12 1995-11-09 Lipidspaltender enzymkomplex

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4440472 1994-11-12
DEP4440472.7 1994-11-12
DE19518278A DE19518278A1 (de) 1994-11-12 1995-05-18 Lipidspaltendes Enzym
DE19518278.2 1995-05-18

Publications (2)

Publication Number Publication Date
WO1996015234A2 WO1996015234A2 (de) 1996-05-23
WO1996015234A3 true WO1996015234A3 (de) 1996-06-20

Family

ID=25941931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/004414 WO1996015234A2 (de) 1994-11-12 1995-11-09 Lipidspaltendes enzym

Country Status (12)

Country Link
EP (1) EP0791056B1 (de)
JP (2) JP3681005B2 (de)
AT (1) ATE292173T1 (de)
AU (1) AU711367B2 (de)
CA (1) CA2204908A1 (de)
DE (1) DE59510996D1 (de)
DK (1) DK0791056T3 (de)
ES (1) ES2239761T3 (de)
HU (1) HUT77486A (de)
NZ (1) NZ295682A (de)
PT (1) PT791056E (de)
WO (1) WO1996015234A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100471526C (zh) 2000-03-31 2009-03-25 施托克赫森有限公司 包括在表面上交联的粉末聚合物的吸液吸收层
EP1460082A1 (de) * 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipidester von clofarabin-derivate
WO2008052722A2 (en) * 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug
EP2070938A1 (de) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabin-Dietherphospholipid-Derivate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020596A1 (de) * 1994-01-28 1995-08-03 Boehringer Mannheim Gmbh Verfahren zur herstellung von unsymmetrischen phosphorsäurediestern

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4026265A1 (de) * 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020596A1 (de) * 1994-01-28 1995-08-03 Boehringer Mannheim Gmbh Verfahren zur herstellung von unsymmetrischen phosphorsäurediestern

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOSTETLER K.Y. ET AL.: "Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 11, 1990, MD US, pages 6112 - 6117, XP000371928 *
PIANTADOSI C. ET AL.: "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, 1991, WASHINGTON US, pages 1408 - 1414, XP002000878 *

Also Published As

Publication number Publication date
PT791056E (pt) 2005-08-31
EP0791056B1 (de) 2005-03-30
ATE292173T1 (de) 2005-04-15
DK0791056T3 (da) 2005-07-04
ES2239761T3 (es) 2005-10-01
NZ295682A (en) 1999-09-29
WO1996015234A2 (de) 1996-05-23
JP2005095178A (ja) 2005-04-14
HUT77486A (hu) 1998-05-28
JP3681005B2 (ja) 2005-08-10
AU711367B2 (en) 1999-10-14
CA2204908A1 (en) 1996-05-23
AU3927895A (en) 1996-06-06
EP0791056A2 (de) 1997-08-27
DE59510996D1 (de) 2005-05-04
JPH10508498A (ja) 1998-08-25

Similar Documents

Publication Publication Date Title
Ortaldo et al. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes
WO1991009958A3 (en) Method of delivering molecules into eukaryotic cells
TR199801680T2 (xx) Beta-laktam antibiyotik i�eren tabletler ve �retim y�ntemi.
DE69334224D1 (de) Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
EP1426058A3 (de) Flüssige Interferon-Beta Formulierungen
WO2006073446A3 (en) Peptide-mediated protein transduction into cells the hematopoietic lineage
AU6821687A (en) System for delivering drug with enhanced bioacceptability
WO1996015234A3 (de) Lipidspaltendes enzym
Eisen Plasma kinins in synovial exudates
ES2004099A6 (es) Procedimiento de preparacion de polipeptidos biologicamente activos
NZ300202A (en) Delivery of collagenase to wounds
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
Ragsdale et al. Characteristics of fibrinolytic enzyme release from human monocytes.
EP1211311A3 (de) Aktivierte Lymphocyten aus Nabelstrangblut und Zusammensetzungen davon
WO1997017072A3 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
ES2145284T3 (es) Derivados del acido dioxo-tiopirano-piridin-carboxilico y su uso como farmacos.
AU2267892A (en) Molecular encapsulation and delivery of alkanes to living mammalian cells for risk assessment and pharmaceutical application
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
FR2752527B1 (fr) Utilisation d'un extrait de bertholletia dans le domaine cosmetique ou pharmaceutique, notamment dermatologique, et pour la preparation de milieux de culture de cellules
AU660438B2 (en) Immobilized D-amino acid oxidase and its use for the preparation of medicaments
Pitts Con A cytotoxicity: a model for the study of key signaling steps leading to lymphocyte apoptosis in AIDS?
NO942228L (no) Ipsapiron-legemiddeltilberedning
Akanji et al. Effect of repeated administration of suramin on alkaline phosphatase activity in rat kidney.
WO1992002612A3 (en) Tissue plasminogen activator variants with decreased clearance
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ EE FI HU JP KR KZ LT LV MX NO NZ PL RO RU SI SK UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ EE FI HU JP KR KZ LT LV MX NO NZ PL RO RU SI SK UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2204908

Country of ref document: CA

Ref country code: CA

Ref document number: 2204908

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 295682

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995937058

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 836046

Date of ref document: 19970708

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995937058

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995937058

Country of ref document: EP